GlassScriptPhysician profile
James W Griffin
NPI 1720274327
$3,547.29
in general payments reported to CMS, 2019-2025
18 companies · $645 in 2025
The $645 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.54 · 2020: $60.24 · 2021: $706 · 2022: $793 · 2023: $854 · 2024: $407 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,906.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $887.75 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $467.40 | 2022-2025 | Pifeltro, Delstrigo, Dificid |
| Abbvie INC. | $405.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $298.29 | 2022-2025 | Breztri, Airsupra, Lokelma |
| Janssen Biotech, INC. | $272.20 | 2020-2023 | Symtuza |
| Glaxosmithkline, LLC. | $241.93 | 2019-2025 | Shingrix, Bexsero |
| Viiv Healthcare Company | $234.49 | 2022-2025 | Rukobia, Dovato |
| Novo Nordisk INC | $193.22 | 2021-2025 | Wegovy |
| Theratechnologies INC. | $114.40 | 2020-2023 | Egrifta Sv |
| Grt US Holding, INC. | $97.45 | 2022 | |
| Medela LLC | $70.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.49 | 2022 | |
| Lilly USA, LLC | $66.59 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Hologic Sales and Service, LLC | $51.17 | 2024-2025 | Aptima |
| Pfizer INC. | $33.11 | 2022-2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $16.17 | 2024 | Nuzyra |
| Averitas Pharma INC. | $14.56 | 2023 | Qutenza |
| Exact Sciences Corporation | $13.83 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.